![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences (E.H., T.F., M.It., T.Y., M.N.), and Department of Obstetrics and Gynecology (S.K., M.In.), Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa, Japan
(Received May 8, 2007; accepted July 19, 2007)
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
to this element. Luciferase assays using MCF-7 cells revealed that the transcriptional activity of the CYP2A6 promoter was significantly activated by estradiol in an ER-dependent manner, in which ERE was responsible for the activation. Chromatin immunoprecipitation assays verified the in vivo association of ER with the ERE on the CYP2A6 gene. Immunohistochemical analyses using human endometrial tissues indicated that the CYP2A6 protein level in glandular cells was significantly higher in the proliferative phase than in the secretory phase, concomitant with local estrogen secretion during the menstrual cycle. These findings clearly demonstrated that CYP2A6 is directly induced by estrogen in an ER-dependent manner, implying a biological role of CYP2A6 in estrogen-responsive tissues. Furthermore, this mechanism can also explain clinical aspects of increased nicotine metabolism under estrogen-rich environments.
), and further to trans-3'-hydroxycotinine (Nakajima et al., 1996a). In addition, CYP2A6 catalyzes the metabolism of coumarin and pharmaceutical agents such as tegafur, losigamone, letrozole, and valproic acid (Nakajima et al., 2002). It can also metabolically activate tobacco-specific nitrosamines such as 4-methylnitrosoamino-1-(3-pyridyl)-1-butanone and N-nitrosodiethylamine (Yamazaki et al., 1992). Although CYP2A6 is mainly expressed in liver, it is expressed in sex steroid-responsive tissues as well, including breast, ovary, uterus, testis, and adrenal grand (Miksys and Tyndale, 2004; Nakajima et al., 2006b). The biological significance of such tissue tropism remains unclear.
Accumulating clinical evidence suggests that CYP2A6 might be regulated by sex hormones. First, sex differences in CYP2A6 activity have been reported. For example, the urinary excretion level of 7-hydroxycoumarin formed from coumarin by CYP2A6 was significantly higher in women than in men (Iscan et al., 1994; Ujjin et al., 2002). The ratio of cotinine/nicotine in plasma was higher in women than in men (Nakajima et al., 2006a). The clearance of nicotine and cotinine has also been reported to be significantly higher in women than in men (Benowitz et al., 2006). Second, the use of oral contraceptives containing estrogen accelerates the clearance of nicotine and cotinine (Benowitz et al., 2006). Third, the clearance of nicotine and cotinine was significantly higher during pregnancy (Dempsey et al., 2002). In addition to these findings, a recent in vitro study demonstrated that the expression level of CYP2A6 mRNA was significantly higher in estrogen receptor (ER; NR3A1)-positive breast tumors than in ER-negative breast tumors (Bièche et al., 2004). This background prompted us to investigate the roles of estrogen in regulating CYP2A6. In the present study, we provide evidence that CYP2A6 is directly induced by estradiol via the binding of ER to a specific sequence on the promoter.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
-[9(4,4,5,5,5-Pentafluoropentylsulfonyl)nonyl]estra-1,3,5(10)-triene-3,17ß-diol (ICI 182,780) and cycloheximide were purchased from Tocris Cookson (Bullwin, MO) and Wako Pure Chemical Industries (Osaka, Japan), respectively. Blend Taq-Plus-was obtained from Toyobo (Osaka, Japan). Oligonucleotides were commercially synthesized at Hokkaido System Sciences (Sapporo, Japan). Mouse anti-human ER monoclonal antibodies and normal mouse IgG were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-human CYP2A6 monoclonal antibodies were obtained from BD Gentest (Woburn, MA). All other reagents were of the highest grade commercially available. Cell Culture. Human breast adenocarcinoma cell lines, MCF-7 and MDA-MB-435, and human hepatocarcinoma cell line HepG2 were obtained from American Type Culture Collection (Manassas, VA). MCF-7 and HepG2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Melbourne, VIC, Australia) and 0.1 mM nonessential amino acids (Invitrogen) at 37°C under 5% CO2. MDA-MB-435 cells were cultured in DMEM supplemented with 10% FBS. Before estradiol treatment, these cells were grown in phenol red-free DMEM (Invitrogen) containing 10% dextran-coated, charcoal-treated FBS for 48 h. Three lots of human cryopreserved hepatocytes, lot 79 (Caucasian, male, 9 months), lot 82 (Hispanic, female, 23 years), and lot 100 (Caucasian, female, 74 years), were purchased from In Vitro Technologies (Baltimore, MD) and maintained in HCM hepatocyte culture medium (Cambrex, East Rutherford, NJ) on collagen-coated plates at 37°C under 5% CO2. Human hepatocytes were seeded into collagen-coated six-well plates at 1 x 106 cells/well. After 24 h, the culture medium was changed to HCM medium (epidermal growth factor- and antibiotic-free) containing 10 nM estradiol or 0.1% (v/v) DMSO vehicle. The cells were maintained for 12 h until harvesting.
Real-Time RT-PCR and Semiquantitative RT-PCR Analyses. Total RNA was isolated from cells using ISOGEN (Invitrogen) following the manufacture's protocol, and cDNA was synthesized as described previously (Nakajima et al., 2006b). The primers for human CYP2A6 (Nakajima et al., 2006b) and GAPDH (Tsuchiya et al., 2004) were described previously. Real-time RT-PCR assays for CYP2A6 and GAPDH were performed by the method previously reported (Nakajima et al., 2006b). This method, however, could not be applied for the quantification of CYP2A6 mRNA in cell lines, because nonspecific PCR products interfered with the quantification owing to low CYP2A6 expression level. Therefore, the CYP2A6 expression levels in cell lines were semiquantitatively determined by measuring the density of the CYP2A6-specific band. The PCR for CYP2A6 was carried out as follows. A 2-µl portion of the reverse-transcribed mixture was added to a PCR mixture containing a 0.4 µM concentration of each primer, 0.2 mM deoxynucleoside-5'-triphosphates, 0.5 U of Blend Taq-Plus-, and 1x buffer for Blend Taq (20 mM Tris-HCl pH 8.0, 100 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 0.5% Tween 20, 0.5% Nonidet P-40, 50% glycerol, and 20 mM MgCl2) in a final volume of 25 µl. The PCR condition was as follows. After an initial denaturation at 96°C for 2 min, the amplification was performed by denaturation at 96°C for 20 s, annealing at 58°C for 20 s, extension at 72°C for 30 s, and cycling immediately for 35 cycles. The PCR condition for human GAPDH was described previously (Nakajima et al., 2006b). The PCR products (10 µl) were analyzed by electrophoresis with 2% agarose gel and visualized by ethidium bromide staining. The density of PCR products was measured by ImageQuant TL (GE Healthcare Bio-Sciences, Little Chalfont, Buckinghamshire, UK).
Electrophoretic Mobility Shift Assays. Human ER protein was synthesized in vitro using the ER expression plasmid (pSG5-HE0) (Tsuchiya et al., 2004) and TNT T7 Quick Coupled Transcription/Translation Systems (Promega, Madison, WI) following the manufacturer's protocol. The oligonucleotide sequences are shown in Table 1. Double-stranded oligonucleotides were labeled with [
-32P]ATP using T4 polynucleotide kinase (Toyobo) and purified by Microspin G-50 columns (GE Healthcare Bio-Sciences). The labeled probe (80 fmol, 
13,000 cpm) was applied to each binding reaction in 25 mM HEPES-KOH (pH 7.9), 0.5 mM EDTA, 50 mM KCl, 10% glycerol, 0.5 mM dithiothreitol, 0.5 mM (p-amidinophenyl) methanesulfonyl fluoride, 2 µg of poly(dI-dC), and 5 µl of in vitro transcribed/translated proteins to a final reaction volume of 15 µl. To determine the specificity of the binding to the oligonucleotides, competition experiments were conducted by coincubation with the unlabeled competitors at 5-, 25-, and 100-fold molar excesses. For supershift experiments, 2 µg of anti-ER antibodies or normal mouse IgG (control) were preincubated with in vitro transcribed/translated proteins on ice for 30 min. The mixtures were incubated on ice for 15 min and then loaded on 4% acrylamide gels in 0.5x Tris-borate EDTA buffer. The gels were dried and exposed to X-ray film for 20 h. The DNA-protein complexes were detected with a Fuji Bio-Imaging Analyzer BAS 1000 (Fuji Film, Tokyo, Japan).
|
Luciferase Reporter Plasmids. Plasmids termed pGL3-2A6/ERE and pGL3-3(2A6/ERE) were constructed by single and triple insertion of the double-stranded oligonucleotides of 2A6/ERE into the pGL3-promoter vector (Promega). A pGL3 plasmid containing the 5'-flanking region from -4102 to -1 of the CYP2A6 gene was previously constructed in our laboratory (Itoh et al., 2006). Using this plasmid, various plasmids were constructed by digestion with restriction enzymes and ligation. A plasmid mutated in the ERE of pGL3-2697/-898 was constructed by site-directed mutagenesis with a QuikChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA). The forward primer was 2A6/ERE-mut as described in Table 1 and the reverse primer was 5'-gtgatcagcAGTTTGccaTGAACTggccagggagg-3', in which hexamer half-sites are capitalized and mutated nucleotides are underlined. Nucleotide sequences were confirmed using Thermo Sequenase Cy5.5 and Cy5 Dye Terminator Cycle Sequencing kits (GE Healthcare Bio-Sciences). A pGL3 plasmid containing three copies of consensus ERE (pGL3-3EREc38) (Komagata et al., 2006) was used as a positive control.
Transfection and Luciferase Assay. MCF-7 cells were seeded into 24-well plates at 4.3 x 104 cells/well and then incubated for 24 h before transfection. Transfection was performed using Tfx-20 reagent (Promega). In brief, the transfection mixture consisted of 490 ng of reporter constructs, 10 ng of control reporter plasmid (phRL-TK), and 500 ng of ER expression plasmid. Twenty-four hours after the transfection, the cells were treated with 10 nM estradiol or DMSO vehicle (0.1%) for 24 h. The cells were harvested and lysed to measure the luciferase activity using a Dual Luciferase Reporter Assay System (Promega). The relative luciferase activities were normalized with the Renilla luciferase activities. For the studies using ER antagonists, MCF-7 cells were transfected with reporter construct without the ER expression plasmid and were incubated with 1 µM ICI 182,780 or 4OHT in the absence or presence of 10 nM estradiol for 24 h.
Chromatin Immunoprecipitation Assay. MCF-7 cells were cultured in a 100-mm dish to 80% confluence. HepG2 cells cultured in a 60-mm dish to 60% confluence were transfected with 5 µg of the ER expression plasmid and incubated for 24 h. These cells were treated with 10 nM estradiol or DMSO vehicle (0.1%) for 12 h. The chromatin immunoprecipitation (ChIP) assay was performed using a ChIP assay kit (Upstate, Charlottesville, VA) according to the manufacturer's protocol. Anti-ER antibodies and normal mouse IgG were used for immunoprecipitation of protein-DNA complex. PCR was performed using primer sets: region 1, forward, 5'-ctcactctgaaagcctgttcc-3' and reverse, 5'-tggctcctccttttccttcg-3'; region 2, forward, 5'-gtctgttttctgtcctctgta-3' and reverse, 5'-atagaacctccactgcccatc-3'. The PCR condition was as follows. After an initial denaturation at 94°C for 3 min, the amplification was performed by denaturation at 94°C for 20 s, annealing at 64°C for 20 s, extension at 72°C for 30 s, and cycling immediately for 30 cycles. The PCR product was electrophoresed on a 2% agarose gel.
Immunohistochemistry of CYP2A6 in Human Endometrial Tissues. Human endometrial tissues were obtained from 19 patients undergoing hysterectomy as a treatment for benign neoplasms not associated with endometrial disease at Kanazawa University Hospital. Written informed consent was obtained from all patients. The collected endometrial tissues were sampled for histopathological diagnosis, and the remaining normal portions of the samples were used for immunohistochemistry. The phase of the menstrual cycle was determined by histological examination of the tissues and also confirmed by determination of the day of the menstrual cycle. Immunohistochemical analyses of CYP2A6 were performed using formalin-fixed, paraffin-embedded specimens of normal endometrial tissues. The sections were incubated with L.A.B. reagent (Polysciences, Warrington, PA) at room temperature for 8 min and then with anti-CYP2A6 antibodies at 4°C for 16 h. Staining reactions were performed using the ABC-elite kit (Vector Laboratories, Burlingame, CA). Staining of glands in functional layers was evaluated by three independent pathologists as positive when >10% of the constituting glandular epithelial cells were stained. The results were judged as - (<10% of the glands at the region of interest), + (>10%), or ++ (>10% with high intensity).
|
|
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
-positive MCF-7 (2.9-fold, P < 0.01) but not in ER-negative MDA-MB-435 cells. To further investigate whether this activation is direct or indirect, MCF-7 cells were treated with estradiol in the presence of cycloheximide, and RT-PCR assays were performed. The induction of CYP2A6 mRNA was not abolished by cycloheximide, indicating that estradiol directly regulates CYP2A6. A significant induction was also observed in HepG2 cells (1.3-fold, P < 0.001), which are known to be estrogen-responsive, although the ER level is low (Marino et al., 2001). Furthermore, real-time RT-PCR assays revealed that CYP2A6 mRNA was significantly increased by the treatment with estradiol in three lots of human hepatocytes (1.5-fold in lot 79 (P < 0.001) and lot 82 (P < 0.01) and 1.2-fold in lot 100 (P < 0.05)). These results suggested that CYP2A6 mRNA was induced by estradiol in an ER-dependent manner.
ER Directly Binds to the ERE on the CYP2A6 Gene. A computer-assisted homology search identified a putative ERE on the CYP2A6 gene at -2436. The sequence of the putative ERE (AGGTCAtggCAACCT) has 2-base pair mismatches compared with the consensus ERE (AGGTCAnnnTGACCT). We therefore sought to determine whether ER directly binds to the putative ERE of the CYP2A6 gene. Electrophoretic mobility shift assays were performed using in vitro transcribed ER and consensus ERE or the putative ERE on the CYP2A6 gene (2A6/ERE) as a probe. We first confirmed that the ER we transcribed with the in vitro system certainly binds to the consensus ERE sequence (Tsuchiya et al., 2004), indicating that the ER we produced worked well (Fig. 2A). This binding was supershifted by ER antibodies and competed out by 2A6/ERE, but not by the mutant sequence (2A6/ERE-mut). When ER was incubated with 2A6/ERE as a probe, we found a specific retarded band, which was supershifted by ER antibodies and competed out by the consensus ERE as well as by the homologous competitor (Fig. 2B). No significant band was observed with 2A6/ERE-mut as a probe (Fig. 2C). These results indicated that ER specifically binds to the ERE on the CYP2A6 gene.
Estradiol Activates CYP2A6 Promoter in ER-Positive Cells. To examine the transcriptional activation of the CYP2A6 gene by estradiol, luciferase assays were performed with a series of reporter plasmids containing the 5'-flanking region of CYP2A6 in MCF-7 cells. We confirmed that the luciferase activity of pGL3-3EREc38 plasmid used as a positive control increased up to 37-fold by estradiol treatment, which was further enhanced by the overexpression of ER (67-fold) (Fig. 3A). Unexpectedly, estradiol treatment did not activate the transcriptional activities of any CYP2A6 constructs. However, in the presence of overexpressed ER, the pGL3-3046 plasmid containing the ERE responded to estradiol treatment (1.4-fold), whereas the pGL3-2157 plasmid lacking it did not.
|
|
). Deletion from -897 to -1 did not result in significant induction of transcriptional activity in response to estradiol treatment (Fig. 3B). However, in the presence of overexpressed ER, their transcriptional activities were enhanced up to 3.7-fold in pGL3-3046/-898 plasmid and 4.3-fold in pGL3-2697/-898 plasmid. Substitution mutations introduced into the ERE of the pGL3-2697/-898 plasmid abrogated the estradiol-induced activation. In the presence of overexpressed ER, the transcriptional activity of the pGL3-2697/-2157 plasmid containing the ERE was moderately activated by estradiol (2.7-fold), whereas that of the pGL3-2157/-898 lacking the ERE was weakened (1.6-fold). To further verify the role of the ERE, we constructed a reporter plasmid pGL3-3(2A6/ERE), in which tandem-repeated ERE was linked to the SV40 promoter. This plasmid dramatically responded to estradiol treatment exhibiting a 38-fold induction of transcriptional activity even in the absence of overexpressed ER, which was largely inhibited by the treatment with ER antagonists ICI 182,780 or 4OHT (Fig. 4). These results clearly indicate that the ERE on the CYP2A6 gene works as a functional element in an ER-dependent manner.
|
|
Is Associated with the ERE on CYP2A6 Gene in Intact Cells. To further investigate the association of ER with the CYP2A6 gene in intact cells, ChIP assays were performed using MCF-7 and ER-overexpressed HepG2 cells. PCR was performed with a primer set for region 1 including the ERE, or for region 2 as a negative control. Normal mouse IgG was used as a negative control of immunoprecipitation for the ChIP assays. As shown in Fig. 5, the immunoprecipitants of estradiol-treated MCF-7 cells obtained with anti-ER antibodies generated a distinct PCR product for region 1, but those obtained with mouse IgG did not. The immunoprecipitants of HepG2 cells obtained with anti-ER antibodies generated a distinct PCR product for region 1, irrespective of estradiol or DMSO treatment. Using the primer set for region 2, no PCR products were generated. These results suggested that ER binds to the CYP2A6 gene in intact cells. Expression of CYP2A6 Protein in Human Endometrial Tissues Is Dependent on the Menstrual Cycle. The endometrium would be a suitable tissue to investigate regulation by estrogen. Immunohistochemistry of CYP2A6 was performed in normal endometrial tissues obtained from 19 patients at different phases of the menstrual cycle. Immunostaining of CYP2A6 was detected in both the glandular epithelial and stromal cells. We evaluated the staining of CYP2A6 in the glandular epithelial cells in functional layers, because they are mostly susceptible to estrogen. Strong staining was observed in the glandular epithelial cells during the proliferative phase (Fig. 6A) and in the early secretory phase, but the staining was diminished in the late secretory phase (Fig. 6B). Of 11 samples in the proliferative phase, 7 and 4 samples were judged as (++) and (+), respectively (Table 2). Of 5 samples in the early secretory phase, 3 and 2 samples were judged as (++) and (+), respectively. In contrast, 3 samples in the late secretory phase were judged as (-). A statistically significant difference in the staining was observed among the different phases of the menstrual cycle (P < 0.001). Although there are genetic polymorphisms in the CYP2A6 gene, we confirmed that none of the 19 patients were homozygotes or combined heterozygotes of the CYP2A6*4 (entire gene deleted) allele and CYP2A6*9 (promoter activity-decreased) allele (data not shown). Thus, the expression levels of CYP2A6 in the glandular cells appeared to be tightly regulated in a menstrual phase-dependent manner, concomitant with the secretion of estradiol.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Dempsey et al., 2002; Benowitz et al., 2006) in which ER plays a central role, because the induction of CYP2A6 mRNA was observed only in ER-positive cells and estradiol-dependent transactivation of the promoter was substantially increased when ER was overexpressed in MCF-7 cells. Furthermore, ER antagonists were able to inhibit the estradiol-induced transactivation of CYP2A6.
The ERE we identified at -2436 on the CYP2A6 gene had 2-base pair mismatches compared with the consensus ERE. Cumulative data from various ER-target genes indicated that some nucleotide differences in the ERE sequence allow the ER to bind. However, the nucleotide changes in both hexamer half-sites decrease the binding of ER compared with those in only one half-site (Klinge, 2001). The fact that ERE on the CYP2A6 gene has the mismatches in only one half-site supports the view that this element functions as the ER binding site. The luciferase analyses showed that the estradiol-dependent transactivation was not fully abolished by the mutation or deletion of the ERE on the CYP2A6 gene, indicating that some other element(s) may also be responsible for the regulation. It is known that ER modulates the activities of other transcription factors such as activator protein-1 (Kushner et al., 2000), specificity protein-1 (Saville et al., 2000), or nuclear factor-
B (Stein and Yang, 1995; Ray et al., 1997) by stabilizing their DNA binding and/or recruiting coactivators to the complex. Moreover, ER could bind an ERE half-site cooperating with specificity protein-1 (Petz and Nardulli, 2000; Vyhlidal et al., 2000). Interestingly, we found two ERE half-sites on -2079 and -2500 of the CYP2A6 gene. Further studies are needed to clarify whether the coactivator-like function of ER is additionally involved in the estradiol-dependent induction of CYP2A6.
In the present data, there is some discrepancy between in vitro and in vivo findings regarding ER dependence for the regulation. The ChIP assay showed that endogenous ER in MCF-7 cells binds to the ERE on CYP2A6 gene in intact cells (Fig. 5), whereas the CYP2A6 promoter was not transactivated by estradiol in MCF-7 cells and overexpressed ER was required for activation in the luciferase reporter assay (Fig. 3). In contrast, the CYP2A6 promoter was not transactivated by estradiol in HepG2 cells, even though ER was overexpressed (data not shown), in contrast to the fact that CYP2A6 mRNA was significantly induced by estradiol in both MCF-7 and HepG2 cells. Therefore, cell type-related conformational and/or epigenetic events may play important roles in this regulation.
Another notable finding we identified is that the expression levels of CYP2A6 protein in endometrial glandular cells was exquisitely regulated in a menstrual phase-dependent manner. The expression pattern of CYP2A6 in endometrial glands is consistent with changes in the local concentration of estradiol (Alsbach et al., 1983) as well as the ER expression (Lecce et al., 2001), again supporting our regulatory model of CYP2A6. This regulatory mechanism may occur in liver, where CYP2A6 is abundantly expressed and estradiol and ER are also distributed, supported by the induction of CYP2A6 by estradiol in human hepatocytes (Fig. 1). Hukkanen et al. (2005), however, reported that the menstrual cycle phase did not affect the nicotine and cotinine clearances. Because these clearances are determined by CYP2A6-dependent metabolism in liver, a small change of the estrogen level during the menstrual cycle might not affect the CYP2A6 expression in liver. The order of changes in the estrogen level and that in the nicotine clearance are the same: sex difference < oral contraceptive use < pregnancy, indicating their association. Thus, the observed sex differences in CYP2A6 activity might be due to the induction by estradiol, although other unknown mechanisms may also be involved. In contrast, oral contraceptive use and pregnancy, which strikingly increase the estrogen level, would result in the significant increases of nicotine clearance by induction of CYP2A6.
What is the biological role of CYP2A6 in estrogen-responsive tissues? At present, we have no conclusive explanation. Many cytochrome P450 isoforms are likely to be induced by the substrates themselves. It has been reported that CYP2A6 catalyzes 16ß-hydroxylation of estradiol and has substantial activity for the conversion of estradiol to estrone and a few dehydro-estradiol metabolites (Lee et al., 2003). Therefore, the regulation of CYP2A6 by estradiol is consistent with this theory. In sex steroid-responsive tissues, sex hormones play pivotal roles in their functions. In particular, estrogen is indispensable for endometrial proliferation to maintain the menstrual cycle. However, such hormonal actions sometimes trigger unexpected molecular events including carcinogenesis when they are overproduced. In the endometrium, excess exposure to estradiol is well recognized as a major etiologic risk factor for endometrial carcinogenesis. The presence and induction of estradiol-metabolizing enzyme(s), including CYP2A6, may play some role in protecting against such adverse effects of estrogen in estrogen-responsive tissues. On the other hand, CYP2A6 catalyzes the metabolic activation of tobacco-specific nitrosamines. It has been reported that female smokers have a higher risk of lung cancer than male smokers (Zang and Wynder, 1996; Henschke and Miettinen, 2004). Smoking is also a risk factor in breast and uterine cervix cancers. Thus, the induction of CYP2A6 by estrogen may be involved in the tobacco-related carcinogenesis in estrogen-responsive tissues.
In summary, we found that human CYP2A6 is induced by estradiol via ER. This study could provide insights into the molecular mechanism of increased nicotine metabolism accompanied by an increased estrogen level. The regulation by estrogen may imply some biological role of CYP2A6 in estrogen-responsive tissues.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
ABBREVIATIONS: ER, estrogen receptor ; 4OHT, 4-hydroxytamoxifen; ChIP, chromatin immunoprecipitation; DMSO, dimethyl sulfoxide; ERE, estrogen response element; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ICI 182,780, 7-[9(4,4,5,5,5-pentafluoropentylsulfonyl-)nonyl]estra-1,3,5(10)-triene-3,17ß-diol; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; ANOVA, analysis of variance.
Address correspondence to: Dr. Miki Nakajima, Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. E-mail: nmiki{at}kenroku.kanazawa-u.ac.jp
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
coactivator 1. J Pharmacol Exp Ther 319: 693-702. to estrogens and antiestrogens. J Steroid Biochem Mol Biol 100: 79-86.[CrossRef][Medline] in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J Clin Endocrinol Metab 86: 1379-1386.B by the estrogen receptor. FEBS Lett 409: 79-85.[CrossRef][Medline]/ß)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275: 5379-5387.B and C/EBPß. Mol Cell Biol 15: 4971-4979.[Abstract]This article has been cited by other articles:
|
|
 |
|
  C. Penaloza, B. Estevez, S. Orlanski, M. Sikorska, R. Walker, C. Smith, B. Smith, R. A. Lockshin, and Z. Zakeri Sex of the cell dictates its response: differential gene expression and sensitivity to cell death inducing stress in male and female cells FASEB J, June 1, 2009; 23(6): 1869 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Derby, K. Cuthrell, C. Caberto, S. G. Carmella, A. A. Franke, S. S. Hecht, S. E. Murphy, and L. Le Marchand Nicotine Metabolism in Three Ethnic/Racial Groups with Different Risks of Lung Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3526 - 3535. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
